Compare Incyte Corporation (INCY) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Paycom Software Inc — how do they compare? Incyte Corporation trades at $119.4 (market cap $24.54B), while Paycom Software Inc trades at $209.22 (market cap $9.57B). The key difference: Incyte Corporation is far larger — about 2.6× Paycom Software Inc's market cap, and Paycom Software Inc pays a 0.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PAYC | |
|---|---|---|
Market Cap | $24.54B | $9.57B |
Sector | Health | Technology |
52-Week High | $129.93 | $233.89 |
52-Week Low | $81.61 | $113.59 |
Enterprise Value | $20.04B | $10.35B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Paycom Software (PAYC) trades at $209.22, down 1.98% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $2.78 per share, beating estimates, and raised its full-year outlook, driven by 10% revenue growth and AI-driven demand. Fundamentals show robust profitability with a 22.78% net income margin and 41.09% ROE, though valuation multiples like P/E of 22.46 are elevated. Recent news highlights operational efficiency and dividend declarations.
The outlook remains positive given consistent earnings beats and raised guidance, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting moderate upside. Investors should weigh strong fundamentals against potential overvaluation and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
